Indaptus Therapeutics Inc. (INDP)

Overview

Indaptus Therapeutics, Inc. is a pioneering clinical biotechnology enterprise, focused on the development of innovative anti-cancer and anti-viral immunotherapy products. Originally known as Intec Parent, Inc., the company underwent a rebranding to Indaptus Therapeutics, Inc. in August 2021, aligning its name with its expansive focus on adaptive immune therapies. Positioned in the bustling hub of New York, New York, Indaptus Therapeutics is at the forefront of crafting cutting-edge treatments with the potential to significantly impact the management and outcomes of some of the most challenging diseases faced today.

Products and Services

The portfolio of Indaptus Therapeutics, Inc. demonstrates a keen focus on the development of therapies with the promise of transforming the landscape of cancer and viral infections treatment. Their emphasis on immunotherapy products tailored to harness the body's own immune system to fight diseases is pivotal. Noteworthy among their contributions is their flagship clinical candidate, Decoy20.

• Decoy20 - Phase 2 Clinical Trial: Decoy20 stands out as Indaptus Therapeutics, Inc.'s leading clinical candidate, currently in Phase 2 of clinical trials. This innovative immunotherapy product aims to catalyze single agent activity and enable combination therapy-based durable responses across various tumors and viral infections. Specifically, Decoy20 is being explored for its potential efficacy in addressing lymphoma, hepatocellular, colorectal, and pancreatic tumors, in addition to chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection. The versatility and broad applicability of Decoy20 underscore Indaptus Therapeutics' commitment to advancing healthcare through resilient and responsive immunotherapeutic solutions.